Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

Anirban Basu, Anand Dalal, Giorgio Walter Canonica, Mark Forshag, Steven W. Yancey, Saurabh Nagar, Christopher F. Bell

Research output: Contribution to journalArticle

Abstract

Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). Methods: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. Results: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. Conclusions: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723–$840 per patient, differences were not statistically significant.

Original languageEnglish
Pages (from-to)121-131
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

Asthma
Economics
Phenotype
Costs and Cost Analysis
Placebos
mepolizumab
Hospital Emergency Service
Hospitalization
Delivery of Health Care
Cost Savings
Standard of Care
Eosinophils
Health Care Costs
Therapeutics

Keywords

  • Cost analysis
  • eosinophilic phenotype
  • exacerbation
  • mepolizumab
  • severe asthma

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. / Basu, Anirban; Dalal, Anand; Canonica, Giorgio Walter; Forshag, Mark; Yancey, Steven W.; Nagar, Saurabh; Bell, Christopher F.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 17, No. 2, 04.03.2017, p. 121-131.

Research output: Contribution to journalArticle

Basu, Anirban ; Dalal, Anand ; Canonica, Giorgio Walter ; Forshag, Mark ; Yancey, Steven W. ; Nagar, Saurabh ; Bell, Christopher F. / Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2017 ; Vol. 17, No. 2. pp. 121-131.
@article{e6c4109cdebe421dab4ae3e2a8c9e24d,
title = "Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype",
abstract = "Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). Methods: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. Results: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. Conclusions: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723–$840 per patient, differences were not statistically significant.",
keywords = "Cost analysis, eosinophilic phenotype, exacerbation, mepolizumab, severe asthma",
author = "Anirban Basu and Anand Dalal and Canonica, {Giorgio Walter} and Mark Forshag and Yancey, {Steven W.} and Saurabh Nagar and Bell, {Christopher F.}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/14737167.2017.1298444",
language = "English",
volume = "17",
pages = "121--131",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

AU - Basu, Anirban

AU - Dalal, Anand

AU - Canonica, Giorgio Walter

AU - Forshag, Mark

AU - Yancey, Steven W.

AU - Nagar, Saurabh

AU - Bell, Christopher F.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). Methods: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. Results: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. Conclusions: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723–$840 per patient, differences were not statistically significant.

AB - Background: Severe eosinophilic asthma patients are at risk of exacerbations, which are associated with substantial costs. Mepolizumab lowers eosinophil levels and reduces exacerbation risk in severe eosinophilic asthma. We evaluated asthma-related exacerbation costs in mepolizumab-treated patients (versus placebo). Methods: A within-trial economic analysis of the Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma (MENSA) trial. Objectives were to quantify the incremental: (1) medical costs of asthma-related exacerbation; (2) asthma-related exacerbation emergency department visit/hospitalization costs; and (3) asthma-related total healthcare resource utilization. Results: Mean medical costs of asthma-related exacerbations at 8 months were $969, $852, and $1692 in the mepolizumab 75 mg intravenous (IV), mepolizumab 100 mg subcutaneous (SC), and placebo groups, respectively (p = 0.16). Mean medical costs from emergency department visits or hospitalizations due to asthma-related exacerbations were $901, $795, and $1557 in the mepolizumab 75 mg IV, mepolizumab 100 mg SC, and placebo groups (p = 0.020). Asthma-related healthcare resource utilization (all services) was lower for the mepolizumab groups versus placebo. Conclusions: Adding mepolizumab to standard-of-care treatment for severe eosinophilic asthma lowered asthma exacerbation-related medical costs/healthcare resource utilization; although the cost savings ranged from $723–$840 per patient, differences were not statistically significant.

KW - Cost analysis

KW - eosinophilic phenotype

KW - exacerbation

KW - mepolizumab

KW - severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85015690518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015690518&partnerID=8YFLogxK

U2 - 10.1080/14737167.2017.1298444

DO - 10.1080/14737167.2017.1298444

M3 - Article

C2 - 28277854

AN - SCOPUS:85015690518

VL - 17

SP - 121

EP - 131

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -